On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus. On November 5th, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of iHealth's COVID-19 Antigen Rapid Test. iHealth has since been a major supplier of at-home tests to the federal government, state governments, nonprofit organizations, and individuals in the U.S. market. In January 2022, iHealth was awarded a contract from the U.S. Department of Defense to deliver 354 million tests to American families. iHealth now brings at-home COVID tests to the Hong Kong market to further fulfill the company’s responsibilities in fighting against the virus.

iHealth COVID-19 Antigen Rapid Test

iHealth COVID-19 Antigen Rapid Test

Regular price: HK$140.00
Sale price: HK$140.00
Regular price
Unit price: per

Shipping calculated at checkout.

The iHealth® COVID-19 Antigen Rapid Test is a lateral flow assay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2.

This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected nasal swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.

This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older, or adult collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.